Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $76.5 million.

  • Pulmonx's Cash & Equivalents rose 2090.76% to $76.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.5 million, marking a year-over-year increase of 2090.76%. This contributed to the annual value of $70.9 million for FY2024, which is 1513.16% down from last year.
  • Per Pulmonx's latest filing, its Cash & Equivalents stood at $76.5 million for Q3 2025, which was up 2090.76% from $75.5 million recorded in Q2 2025.
  • In the past 5 years, Pulmonx's Cash & Equivalents ranged from a high of $209.3 million in Q1 2021 and a low of $63.3 million during Q3 2024
  • Its 5-year average for Cash & Equivalents is $110.2 million, with a median of $101.6 million in 2023.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 118860.91% in 2021, then tumbled by 4023.55% in 2022.
  • Quarter analysis of 5 years shows Pulmonx's Cash & Equivalents stood at $148.5 million in 2021, then plummeted by 31.48% to $101.7 million in 2022, then dropped by 17.88% to $83.5 million in 2023, then dropped by 15.13% to $70.9 million in 2024, then increased by 7.96% to $76.5 million in 2025.
  • Its Cash & Equivalents was $76.5 million in Q3 2025, compared to $75.5 million in Q2 2025 and $74.6 million in Q1 2025.